DOAC interruption study for Chinese people with atrial fibrillation
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial studies how safely and effectively to pause a blood thinner (a DOAC) for about 48 hours before an elective procedure in people with atrial fibrillation. It may help confirm the best way to reduce bleeding risk without raising stroke risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have atrial fibrillation and it is not related to heart valve problems (nonvalvular).
- You are Chinese and 18 to 80 years old.
- You have been taking a DOAC (apixaban, dabigatran, edoxaban, or rivaroxaban) for at least 6 months.
- You are planning an elective procedure where your clinician advises stopping the DOAC for 48 hours.
- You have not had a major bleeding event or a blood clot/major stroke while on your DOAC.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares whether you should temporarily stop your blood thinner (DOAC) or keep taking it when you have an elective heart catheter test or procedure (coronary angiography or PCI). It aims to see which approach is safer and better for preventing bleeding and clotting around the procedure.
This trial tests whether it is safe for patients with atrial fibrillation to stop taking blood thinners after they have had heart surgery, including closure of the left atrial appendage. The goal is to see if these patients can avoid long-term medication without increasing the risk of stroke.
This study compares different blood-thinner (“antithrombotic”) strategies in people with atrial fibrillation or flutter who recently had a stent placed (PCI). It aims to find a plan that lowers clot risk while keeping bleeding risk as low as possible.
This trial tests whether patients who receive a special device to close a hole in the heart (to prevent stroke from irregular heartbeat) can safely take fewer blood-thinning medications afterward. The study compares taking a standard blood thinner for 3 months versus taking aspirin only, to see which approach works best with fewer bleeding risks.
This trial follows people with atrial fibrillation to see how long-term blood-thinning treatment affects outcomes over time. It may help determine which long-term approach best lowers stroke and clot risks for patients like you.
This trial tests whether taking a blood thinner can lower the risk of stroke in people who had atrial fibrillation (an irregular heartbeat) that happened temporarily around a stressful illness or surgery. It looks especially at people at higher risk for stroke after that episode.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.